Two molecularly targeted drugs that have already been shown to improve outcomes in patients with advanced-stage lung cancer will be tested in early-stage lung cancer in a new clinical trial that will be spearheaded at Dana-Farber Cancer Institute. Geoffrey Oxnard, assistant professor of medicine at Dana-Farber Cancer Institute and Brigham and Women’s Hospital, is quoted.
News & Research
